RxDoctor Payments Data

James Washburn, MD

Pulmonary Disease · Durango, CONPI 1902870009

Payments from drug & device makers

$12,523in general payments, 2019–2025

Across 37 payments — averaging $338.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$12K
  • AstraZeneca$137
  • Boehringer Ingelheim$131
  • Sanofi$125
  • GSK$58
  • Grifols USA, LLC$57
  • plus $93 from 5 others

What the payments were for

  • Travel & lodging$1,1559%
  • Food & beverage$8217%
  • Education$10,54884%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,523 in reported general payments places this provider in the 70th percentile of 248 pulmonary disease providers in Colorado.

See all pulmonary disease providers in Colorado

Medicare billing

Part B allowed, 2024
$55,467
Medicare patients
417
Services billed
1,124

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate33$398,971
Trelegy ElliptaFluticasone/Umeclidin/Vilanter65$53,660
Ambrisentan14$39,900
Spiriva RespimatTiotropium Bromide35$31,996
Breo ElliptaFluticasone/Vilanterol11$10,330
Fluticasone-SalmeterolFluticasone Propion/Salmeterol28$7,069
Incruse ElliptaUmeclidinium Bromide14$7,044
SymbicortBudesonide/Formoterol Fumarate18$5,236
Sirolimus11$4,060
Advair HfaFluticasone Propion/Salmeterol11$3,328
Albuterol Sulfate HfaAlbuterol Sulfate62$2,672
Ventolin HfaAlbuterol Sulfate37$2,313
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate11$2,101
Roflumilast15$1,144
Montelukast Sodium117$986

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat$131$430,96768 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$58$71,03490 claims
AstraZenecaSymbicort$137$5,23618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 248 pulmonary disease providers in Colorado.

Other pulmonary disease in Durango

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →